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Available online 24 November 2015We studied the efﬁcacy of drugs indicated for mitochondrial dysfunction in the treatment of 21 patients with
acute encephalopathywith onset of febrile convulsive status epilepticus at our hospital from January 2006 to De-
cember 2014. Among them, 11 patients had been treatedwith amitochondrial drug cocktail consisting of vitamin
B1, vitamin C, biotin, vitamin E, coenzyme Q10, and L-carnitine (prescription group) and 10 patients were not
treated with the cocktail (non-prescription group).We retrospectively reviewed age, trigger, clinical form, treat-
ment start time, and sequelae. Clinical formwas classiﬁed into a biphasic group presenting acute encephalopathy
with biphasic seizures and late reduced diffusion (AESD) and a monophasic group. Sequelae were classiﬁed as
(A) no sequelae group or (B) sequelae group, and differences in the interval between diagnosis and treatment
were also evaluated. The sequelae were not different between the mitochondrial drug cocktail prescription
and non-prescription groups, but signiﬁcantly better in the group administered the mitochondrial drug cocktail
within 24 h (P = 0.035). We expect that early treatment with a mitochondrial drug cocktail could prevent se-
quelae in acute encephalopathy with onset of febrile convulsive status epilepticus.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Febrile convulsive status epilepticus1. Introduction
Acute encephalopathywith onset of febrile convulsive status epilep-
ticus has mainly been reported in East Asia and is classiﬁed into several
subtypes according to the clinical course and neuroimaging ﬁndings.
Acute encephalopathywith onset of febrile convulsive status epilepticus
can be difﬁcult to distinguish from febrile seizure status and often re-
sults in severe neurological dysfunction. In some patientswith acute en-
cephalopathy with onset of febrile convulsive status, the epilepticus
shows a biphasic course, and such cases are designated as acute enceph-
alopathy with biphasic seizures and late reduced diffusion (AESD) [19].
AESD is clinically characterized by prolonged (N30min) febrile seizures
as the initial neurological symptomon day 1, followed by secondary sei-
zures (most often in a cluster of complex partial seizures) associated
with deterioration of consciousness level at days 4 to 6. Between the bi-
phasic seizures, most patients present continuous disturbance of con-
sciousness level, but some patients have normal, clear consciousnesshasic seizures and late reduced
arnitine palmitoyl transferase II.
, Chiba Children's Hospital, 579-
. This is an open access article underwith no neurological symptoms, which may lead to an initial misdiag-
nosis of febrile seizure status. MRI shows no acute abnormality during
the ﬁrst two days, but reduced diffusion appears in the subcortical
white matter during days 3 to 9 [19,20,22].
One possible cause of acute encephalopathy is depletion of energy
resulting from decreased mitochondrial function [11]. In mitochondrial
diseases, various vitamins and coenzymes have been used clinically
based on their effects on energy shortage and oxidative stress [13],
and effectiveness has been reported at high doses [12]. Therefore, this
study aimed to examine the efﬁcacy of a combination of vitamin B1, vi-
tamin C, biotin, vitamin E), coenzyme Q10, and L-carnitine as a mito-
chondrial drug cocktail in the treatment of acute encephalopathy.2. Methods
We deﬁned acute encephalopathy based on criteria that have been
reported as follows: (a) acute onset of severe and sustained impairment
of consciousness after a preceding infection and (b) exclusion of CNS in-
ﬂammation [5,10,15], in addition to level of consciousness equal to or
below 13 on the Glasgow Coma Scale and duration of impairment lon-
ger than 24 h, according to the diagnostic criteria of the Japanese re-
search committee on inﬂuenza encephalopathy. Following a previousthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1






1 M 62 Influenza A virus Monophasic A
2 F 13 HHV–6 Monophasic A
3 M 13 HHV–6 AESD A
4 F 7 HHV–6 AESD A
5 M 171 Influenza A virus Monophasic A
6 F 63 Enterovirus AESD B
7 F 64 Unknown Monophasic B
8 F 36 Rotavirus AESD A
9 M 21 Unknown AESD B
10 F 28 Influenza A virus AESD A 
11 F 11 Unknown AESD B
12 F 19 Influenza A virus Monophasic B
13 M 14 Unknown Monophasic A
14 M 9 HHV–6 AESD A
15 F 76 Unknown Monophasic B
16 F 17 HHV–6 AESD B
17 F 58 Unknown Monophasic B
18 M 72 Unknown AESD B
19 F 35 Unknown Monophasic A
20 F 47 Rota virus Monophasic A
21 F 54 HHV–6 AESD B
Sequelae were classiﬁed as A; no, B; mild-moderate, or C; severe.
Patients administered the mitochondrial drug cocktail are colored gray (within 24 h are
colored dark gray).
58 T. Omata et al. / Journal of the Neurological Sciences 360 (2016) 57–60report [25], we deﬁned febrile convulsive status epileptics as febrile sei-
zures longer than 30 min. We retrospectively reviewed the medical re-
cords of the patients that the attending physician diagnosed with acute
encephalopathy at our hospital from January 2006 to December 2014.
Then,we selected patients thatmet the criteria described above. The ce-
rebrospinal ﬂuid was examined in all cases, and CNS inﬂammation was
excluded.
There were 23 patients with acute encephalopathy with febrile con-
vulsive status epilepticus as an initial neurological symptom. Among
them, 11 patients (Patients 1 to 11) had been treatedwithmitochondrial
drug cocktails at our hospital since January 2009 (prescription group),
after informed consent was obtained from the patient's family. For the
mitochondrial drug cocktail, we used vitamin B1 (10 mg/kg), vitamin C
(100 mg/kg), biotin (0.5 mg/kg), vitamin E (10 mg/kg), coenzyme Q10
(5 mg/kg), and L-carnitine (30 mg/kg). In all 10 patients, the 6 drugs
were administered orally, except for 2 cases: patient 3 in which only vi-
taminCwas administered via an intravenous drip, andpatient 6 inwhichTable 2







Median age (months) 44.4 40.1
Gender (male) 4 3
Trigger
HHV-6 3 3




Clinical form (AESD) 7 4only vitamin B1 was administered through an intravenous drip. The
cocktail administration period was deﬁned as more than 5 days and
until the medical condition was stable. As an additional treatment, ste-
roid pulse therapy was started within 24 h of encephalopathy diagnosis
in all 11 cases. A single course of steroid pulse therapy consisted of
30 mg/kg/day methylprednisolone for 3 days (cases 3 and 4 received 2
courses of steroid pulse therapy). Age, trigger, clinical form, time of initial
treatment, and sequelae were retrospectively reviewed using medical
records. For clinical form, AESD was diagnosed by the presence of both
biphasic clinical course and MRI ﬁndings of late reduced diffusion.
There were 10 patients (all 6 patients with onset prior to January
2009, and 4 patients with the onset after January 2009, for whom we
have not been involved in the initial treatments) with acute encepha-
lopathy and onset of febrile convulsive status epilepticus at our hospital
who were not treated with the mitochondrial drug cocktail (non-pre-
scription group; patients 12 to 21). All of the non-prescription patients
also received steroid pulse therapy that startedwithin 24 h of diagnosis.
Two patients of the remaining 23 patients were excluded because
only part of the six cocktail drugs was administered.
Sequelae were classiﬁed as (A) no sequelae group (having no obvi-
ous functional decline in motor or intelligence function) or
(B) sequelae group (all others). The family and attending physician
had determined the presence or absence of sequelae at the time of hos-
pital discharge. The sequelae (A vs. B) of themitochondrial drug cocktail
prescription and non-prescription groups were compared. In addition,
the sequelae of the total 21 patients (A vs. B) based on the treatment ini-
tiation time, i.e., within 24 h and others (over 24 h and non-
prescription), were analyzed.
For statistical analysis, we employed the Fisher's exact test for com-
parison of case history between prescription group and non-
prescription group, treatment initiation time within 24 h and others,
and sequelae between the mitochondrial drug cocktail prescription
andnon-prescription groups. Student's t-testwas applied to the average
age values in the prescription and non-prescription groups and treat-
ment initiation time within 24 h and others. In all patients, blood glu-
cose, lactate, ammonia, pH, base deﬁcit, and anion gap levels were
examined, and normal values were conﬁrmed during the course of the
study. Additionally, in the past family history of the patients, there
was nothing relevant to congenital metabolic disorders, and patients
with suspected congenital metabolic abnormalities were not present.
There were no patients who had been administered valproic acid or an-




The 21 cases are summarized in Tables 1, 2. For the 11 patients in the
prescription group, patient age ranged from 7 to 171 months (mean,Treatment initiation time
n = 21





0.798 53.2 39.0 0.474
1.000 3 4 0.182
1.000 3 3 0.115
0.587 2 2 0.228
1.000 0 2 1.000
1.000 0 1 1.000
0.268 0 8 0.111
0.395 2 9 0.635
Table 3
The effect of the mitochondrial drug cocktail (total 21 patients).
Group A: None B: Sequelae Total P value
Prescription 7 (33%) 4 (19%) 11 (48%) 0.395
Non-prescription 4 (19%) 6 (29%) 10 (48%)
Total 11 (52%) 10 (52%) 21 (100%)
Table 5
Effect of the mitochondrial drug cocktail (10 monophasic patients).
Group A: None B: Sequelae Total P value
Prescription 3 (30%) 1 (10%) 3 (30%) 0.571
Non-prescription 3 (30%) 3 (30%) 6 (60%)
Total 6 (60%) 4 (40%) 10 (100%)
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human herpes virus 6 (HHV-6) (3 cases), inﬂuenza A virus (3 cases), ro-
tavirus (1 case), enterovirus (1 case), and unknown (3 cases). The clin-
ical form of acute encephalopathy was AESD in 7 patients and
monophasic in 4 patients. For the 10 patients in the non-prescription
group, patient age ranged from 9 to 76 months (mean, 40.1 months),
and the trigger pathogens were as follows: HHV-6 (3 cases), inﬂuenza
A virus (1 case), rotavirus (1 case), unknown (5 cases). The clinical
form of acute encephalopathy was AESD in 4 patients and monophasic
in 6 patients (Tables 1, 2). There was no signiﬁcant difference in the
case history both between prescription group and non-prescription
group, and between treatment initiation time within 24 h and others
(Table 2). In 10 cases (except for patient 8), the mitochondrial drug
cocktail administration period was 5 to 23 days, with an average of
11.5 days. Patient 8 originally showed poorweight gain, and to consider
the possibility of mitochondrial respiratory chain disorders, we contin-
ued the treatment for 10months after encephalopathy until normal en-
zyme activity was conﬁrmed by skin biopsy.
3.2. Sequelae
The distribution of the 21 patients was as follows: A, 11 cases; B, 10
cases. For the 11 patients in the prescription group, the distributionwas
as follows: A, 7 cases; B, 4 cases. The distribution for the 10 patients in
the non-prescription group was as follows: A, 4 cases; B, 6 cases
(Table 3). The patients were further divided into a biphasic group
(AESD) and a monophasic group based on the clinical form of acute en-
cephalopathy. For the 7 patients in the prescription group with AESD,
the distribution was as follows: A, 4 cases; B, 3 cases. For the 4 patients
in the non-prescription group with AEDS, the distribution was as fol-
lows: A, 1 case; B, 3 cases (Table 4). For the 3 patients in the prescription
group with monophasic acute encephalopathy, the distribution was as
follows: A, 2 cases; B, 1 case. For the 6 patients in the non-prescription
group with monophasic acute encephalopathy, the distribution was as
follows: A, 3 cases; B, 3 cases (Table 5).
There was no signiﬁcant difference in the distribution of the severity
of sequelae (A vs B) between the mitochondrial drug cocktail prescrip-
tion and non-prescription groups in the total 21 patients and in both
AESD and monophasic groups (Tables 3, 4, 5).
3.3. Importance of the time of treatment initiation
Finally, the total 21 patients' sequelae were compared based on the
mitochondrial drug cocktail treatment initiation time: within 24 h and
others (over 24 h or non-prescription). The sequelae of the 5 patients
treated within 24 h of diagnosis were as follows: A, 5 cases; B, 0 cases.
The sequelae of the 16 patients (treated over 24 h or non-
prescription) were as follows: A, 10 cases; B, 11 cases. Sequelae were
signiﬁcantly better in the group administered the drug cocktail within
24 h (P = 0.035) (Table 6).Table 4
Effect of the mitochondrial drug cocktail (11 AESD patients).
Group A: None B: Sequelae Total P value
Prescription 4 (36%) 3 (27%) 7 (64%) 0.303
Non-prescription 1 (9%) 3 (27%) 4 (36%)
Total 5 (45%) 6 (55%) 11 (100%)4. Discussion
We studied the efﬁcacy of a mitochondrial drug cocktail in the treat-
ment of acute encephalopathy with onset of febrile convulsive status
epilepticus. The most important ﬁnding in this study was that sequelae
were signiﬁcantly better in the group administered mitochondrial drug
cocktail within 24 h.
The mechanism of acute encephalopathy with onset of febrile con-
vulsive status epilepticus has not been sufﬁciently elucidated, and the
condition is often classiﬁed into subtypes such as AESD, acute necrotiz-
ing encephalopathy (ANE), and other monophasic types in Japan [11,
24]. Excitotoxic injury with delayed neuronal death has been hypothe-
sized as a possiblemechanism of AESD, based onMR spectroscopic ﬁnd-
ings [11,20] and cytokine analysis of cerebrospinal ﬂuid [7].
Acute encephalopathy is more common in East Asia than in Europe
or North America, indicating that genetic factors play an important
role [2,11]. Carnitine palmitoyl transferase II (CPTII) polymorphisms
[2,17], SCN1A mutations [14], and adenosine A2A receptor polymor-
phisms [16] have recently been reported as predisposing factors for
the onset of acute encephalopathy. Among them, CPTII is themost likely
etiological candidate for encephalopathy. A thermolabile CPTII pheno-
type and a CPTII polymorphism in Japanese patients with multiple
types of acute encephalopathy have been reported [2,17]. Given that
CPTII is an enzyme localized on the mitochondrial inner membrane
that removes fatty acids from carnitine, CPTII deﬁciency leads to mito-
chondrial dysfunction and a lack of energy in the wake of severe infec-
tions [1,6,17,23]. Although further studies should target the
relationship between CPTII polymorphism and treatment efﬁcacy, the
demonstrated involvement of mitochondrial dysfunction in acute en-
cephalopathy suggests that mitochondrial drug cocktails should be ex-
plored for the treatment of acute encephalopathy [3].
There are no established treatments for mitochondrial dysfunction,
but various vitamins and coenzymes have been clinically used based
on their effects on energy shortage and oxidative stress [13], and effec-
tiveness at high dose has already been reported [12]. Therefore, we
employed vitamin B1 (10 mg/kg), vitamin C (100 mg/kg), biotin
(0.5 mg/kg), vitamin E (10 mg/kg), coenzyme Q10 (5 mg/kg), and L-
carnitine (30mg/kg) as amitochondrial drug cocktail based on previous
reports [4,9,12,13,21]. We started prescribingmitochondrial drug cock-
tails to patients with acute encephalopathy approximately 6 years ago
after obtaining informed consent. Although the dose of the mitochon-
drial drug cocktail was consistent and administration was subject to a
uniﬁed protocol, the time from diagnosis to the start of prescription dif-
fered among the cases because their physicians determined their appli-
cations independently.
In this study design, there was no signiﬁcant difference in the aver-
age age of the patients in the prescription and non-prescription groups.
Although no signiﬁcant relationship has been reported between theTable 6
Effect of the mitochondrial drug cocktail (total 21 patients based on the treatment initia-
tion time: within 24 h vs. others).




Within 24 h 5 (24%) 0 (0%) 5 (24%) 0.035
Others (over 24 h or non-prescription) 6 (28%) 10 (48%) 16 (76%)
Total 11 (52%) 10 (48%) 21 (100%)
60 T. Omata et al. / Journal of the Neurological Sciences 360 (2016) 57–60trigger pathogen and the type of encephalopathy [11,17], we found that
HHV6was themost common pathogen, followedby the inﬂuenza virus;
this ﬁnding is in agreement with those of previous reports [8,18].
There was no signiﬁcant difference in prognosis (A vs B) between
the mitochondrial drug cocktail prescription and non-prescription
groups among the 21 patients and in both AESD and monophasic
groups, probably because of the small number of patients and the
delay in starting the mitochondrial drug cocktail after the diagnosis of
encephalopathy. However, no sequelae were observed in the 5 cases
inwhichmitochondrial drug cocktail administrationwas initiatedwith-
in 24 h of encephalopathy diagnosis. Given that the outcomewas signif-
icantly better in the group administered the mitochondrial drug
cocktails within 24 h, we consider that early administration within
24 h of diagnosis may provide a prophylactic effect.
Although there are reports of various vitamins and coenzymes as
treatments for mitochondrial diseases [4,9,12,13,21] and a report of
the combination of creatine monohydrate, coenzyme Q10, and alpha-
lipoic acid as a “mitochondrial cocktail” for mitochondrial cytopathies
[4], there are no reports in which a combination of various vitamins
and coenzymes was administered for acute encephalopathy. Consider-
ing themechanisms of these constituents, it is likely that themitochon-
drial drug cocktail used in this study provides an effective treatment for
acute encephalopathy. Moreover, there have been no obvious side ef-
fects in our patients, and administration of the drug cocktail was rela-
tively easy.
The limitations of our study stem from retrospective analysis and the
small number of patient, further prospective study in larger cohorts is
necessary to conclude the observations; however, we consider that
speedy administration of mitochondrial drug cocktails is worthwhile
in cases of acute encephalopathy and in individuals with a high risk of
encephalopathy (such as those with status epilepticus or spasm of the
cluster associatedwith fever) because of the potential to prevent thede-
velopment of sequelae or the onset of acute encephalopathy.
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